Perform Another (Advanced) Search

1.  Study Posting (1918) Trial #159190, Solid Tumors, Savannah, GA
...of Breath in Patients With Cancer URCC U1701 RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial ...
...as days 1-5 or day 1-day 8 regimens and may include oral regimens • Dyspnea as a symptom within the past 5 days (defined by a score of at least ...
View Page

2.  Study Posting (4519) Trial #106012, Congestive Heart Failure, Vancouver, BC, Canada
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Status: Completed Protocol Number: CAN0010 Sponsor: Company Division: Diagnostic Official Scientific Title: The 'improved management ...
...and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement ...
View Page

3.  Study Posting (4519) Trial #106011, Congestive Heart Failure, Toronto, ON, Canada
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Status: Completed Protocol Number: CAN0010 Sponsor: Company Division: Diagnostic Official Scientific Title: The 'improved management ...
...and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement ...
View Page

4.  Study Posting (4519) Trial #106014, Congestive Heart Failure, Quebec, QC, Canada
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Status: Completed Protocol Number: CAN0010 Sponsor: Company Division: Diagnostic Official Scientific Title: The 'improved management ...
...and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement ...
View Page

5.  Study Posting (4519) Trial #106009, Congestive Heart Failure, Montreal, QC, Canada
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Status: Completed Protocol Number: CAN0010 Sponsor: Company Division: Diagnostic Official Scientific Title: The 'improved management ...
...and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement ...
View Page

6.  Study Posting (4519) Trial #106013, Congestive Heart Failure, Hamilton, ON, Canada
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Status: Completed Protocol Number: CAN0010 Sponsor: Company Division: Diagnostic Official Scientific Title: The 'improved management ...
...and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement ...
View Page

7.  Study Posting (4519) Trial #106008, Congestive Heart Failure, Halifax, NS, Canada
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Status: Completed Protocol Number: CAN0010 Sponsor: Company Division: Diagnostic Official Scientific Title: The 'improved management ...
...and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement ...
View Page

8.  Study Posting (4519) Trial #106010, Congestive Heart Failure, Calgary, AB, Canada
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Status: Completed Protocol Number: CAN0010 Sponsor: Company Division: Diagnostic Official Scientific Title: The 'improved management ...
...and the prediction of clinical outcomes in patients who present to emergency departments with acute dyspnea. Patients will be randomized to a conventional care group, or to conventional care plus measurement ...
View Page

9.  CenterWatch: Clinical Trials in Category (162) Congestive Heart Failure
...A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Halifax, NS : Research Site: A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea. Hamilton, ON : Research Site: A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in ...
View Page

10. Clinical Trial Results by Drug Names
...and the predication of clinical outcomes in patients who present to emergency departments with acute dyspnea. Study center(s) : 7 in Canada. Objectives: To accurately estimate the difference in sensitivity and ...
...of NT-proBNP as a tool to diagnose or exclude CHF for patients presenting with dyspnea to the urgent care facilities in a Canadian setting; to identify the costs and benefits ...
View Page

11.  Newly Approved Drug Therapies (384) Sclerosol Intrapleural Aerosol, Bryan Corporation,
...the prevention of recurrence of malignant pleural effusions in symptomatic patients. Symptoms include chest pain, dyspnea, and coughing. It is to be administered by aerosol during thracoscopy or open thoracotomy. Jobson ...
View Page

12.  Newly Approved Drug Therapies (715) Natrecor (nesiritide), Scios,
...from baseline in pulmonary capillary wedge pressure (PCWP) and the change from baseline in subjects' dyspnea (abnormal breathing), evaluated after three hours. Results demonstrated that subjects receiving Natrecor reported greater improvement in their dyspnea at three hours than subjects receiving placebo. Additionally, there was a greater reduction in mean ...
View Page

13.  Study Posting (4519) Trial #122663, Chest Pain, Zurich, Switzerland
...Primary Outcome: Key Secondary Outcomes: Inclusion Criteria: • adult patients >=18 years of age; • chest pain; • dyspnea. Exclusion Criteria: • onset of symptoms >=5 days before attending hospital; • therapeutic doses of heparin for ...
View Page

14.  Newly Approved Drug Therapies (346) Neumega, Genetics Institute,
...required. Side Effects The most common adverse effects associated with Neumega treatment included peripheral edema, dyspnea, tachycardia, and conjunctival redness. Jobson Medical Information • Privacy | • Glossary Copyright © 1995-2010 Jobson Medical Information ...
View Page

15.  Study Posting (4721) Trial #153283, Emphysema, Seattle, WA
...40 to 74 years of age or older • Candidates have upper lobe, emphysema and severe dyspnea • Must be able to participate in standard exercise testing • Willing to abstain from cigarette smoking ...
View Page

16.  Study Posting (4721) Trial #153282, COPD (Chronic Obstructive Pulmonary Disease), Seattle, WA
...40 to 74 years of age or older • Candidates have upper lobe, emphysema and severe dyspnea • Must be able to participate in standard exercise testing • Willing to abstain from cigarette smoking ...
View Page

17.  Newly Approved Drug Therapies (785) Remodulin (treprostinil), United Therapeutics,
...6-minute walking distance and level of shortness of breath during this physical test (Borg dyspnea score). The primary endpoint was change in 6-minute walking distance over the 12-week ...
...achieve conventional levels of statistical significance. There was a statistically significant change in subjects' Borg dyspnea scores with the Remodulin treatment. There were significant differences between Remodulin- and placebo-treated subjects ...
View Page

18.  Study Posting (4519) Trial #100053, Emphysema, Edinburgh, United Kingdom
...Secondary Outcomes: 1. Efficacy: Spirometry, arterial blood gas, gas transfer, TLco, lung volume, exercise test, dyspnea index, QoL, plasma biomarkers Safety: Adverse events, skin effects, serum lipids, liver enzymes, psychiatric effects ...
View Page

19.  Study Posting (4519) Trial #97583, Emphysema, Cambridge, United Kingdom
...Secondary Outcomes: 1. Efficacy: Spirometry, arterial blood gas, gas transfer, TLco, lung volume, exercise test, dyspnea index, QoL, plasma biomarkers Safety: Adverse events, skin effects, serum lipids, liver enzymes, psychiatric effects ...
View Page

20.  Study Posting (4519) Trial #100860, Emphysema, Birmingham, United Kingdom
...Secondary Outcomes: 1. Efficacy: Spirometry, arterial blood gas, gas transfer, TLco, lung volume, exercise test, dyspnea index, QoL, plasma biomarkers Safety: Adverse events, skin effects, serum lipids, liver enzymes, psychiatric effects ...
View Page